Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 11/01/22
End: 11/01/24
Due: 11/01/25
Phase: N/A
Priority: Normal
Start: 10/01/19
End: 12/31/23
Due: 12/31/24
Phase: N/A
Priority: Normal
Start: 07/15/24
End: 07/15/26
Due: 07/15/27
Phase: N/A
Priority: Normal
Start: 05/01/25
End: 05/01/28
Due: 05/01/29
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| Venetoclax Plus RIC Regimen Allo-HSCT for Elderly Patients With High-risk Myeloid Malignancies | NCT05583175 | Xianmin Song, MD | user2@example.com | None | 2022-11-01 | 2024-11-01 | 2025-11-01 | - | - | 2025-07-14 |
| Next Generation Sequencing（NGS）Monitors Minimal Residual Disease（MRD）in Allo-PBSCT Patients | NCT04126967 | Xianmin Song, MD | user2@example.com | None | 2019-10-01 | 2023-12-31 | 2024-12-31 | - | - | 2025-07-14 |
| RIC With Thiotepa Combined With Bu/Flu/Ara-C in Allo-HSCT for Relapsed or Refractory PTCL. | NCT06468267 | Xianmin Song, MD | user2@example.com | None | 2024-07-15 | 2026-07-15 | 2027-07-15 | - | - | 2025-07-14 |
| Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL | NCT06930105 | Xianmin Song, MD | user2@example.com | None | 2025-05-01 | 2028-05-01 | 2029-05-01 | - | - | 2025-07-14 |